Standard antibiotic prophylaxis

PreclinicalSmall molecule

Standard antibiotic prophylaxis is one of 38 small molecule programs targeting Surgical Site Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Surgical Site InfectionRecruiting

Cesarean SectionActive, not recruiting

Surgical Site InfectionPreclinical

Recruiting

Cesarean SectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

230 competitors in Cesarean Section

#DrugCompanyPhaseTrials

Marcaine

IInnocoll

Preclinical

21 2

Pitocin

RRetrophin

Preclinical

16 3

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

12 4

Neo-Synephrine

EExela Pharma Sciences, LLC.

Preclinical

11 5

Dynastat

Pfizer

Preclinical

1 6

Proamatine

Takeda

Preclinical

1 7

Duragesic

CCephalon

Preclinical

6 8

Xylocaine

MMEDRx USA, Inc.

Preclinical

4 9

Catapres

Boehringer Ingelheim

Preclinical

4 10

Versed

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Surgical Site Infection

NCT07311395

Clinical

Trials by Indication[1]

Antibiotic Prophylaxis1 trial

Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery

Recruiting·—·Phase 3·NCT05502380·1,100 enrolled

Surgical Site Infection1 trial

Local Subcutaneous Administration of Gentamicin for the Prevention of Surgical Site Infection Following Elective Cesarean Section: A Randomized Controlled Pilot Study.

Recruiting·WWestern Galilee Hospital-Nahariya·Preclinical·NCT07311395·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Standard antibiotic prophylaxis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard antibiotic prophylaxis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard antibiotic prophylaxis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Western Galilee Hospital-Nahariya company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWestern Galilee Hospital-Nahariya

Standard antibiotic prophylaxis

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Antibiotic Prophylaxis1 trial

Surgical Site Infection1 trial

References

Drug Info

Quick Facts

Related News